The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen
- PMID: 9875847
- DOI: 10.1016/s0092-8674(00)81717-1
The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen
Abstract
Ligand-dependent activation of transcription by nuclear receptors (NRs) is mediated by interactions with coactivators. Receptor agonists promote coactivator binding, and antagonists block coactivator binding. Here we report the crystal structure of the human estrogen receptor alpha (hER alpha) ligand-binding domain (LBD) bound to both the agonist diethylstilbestrol (DES) and a peptide derived from the NR box II region of the coactivator GRIP1 and the crystal structure of the hER alpha LBD bound to the selective antagonist 4-hydroxytamoxifen (OHT). In the DES-LBD-peptide complex, the peptide binds as a short alpha helix to a hydrophobic groove on the surface of the LBD. In the OHT-LBD complex, helix 12 occludes the coactivator recognition groove by mimicking the interactions of the NR box peptide with the LBD. These structures reveal the two distinct mechanisms by which structural features of OHT promote this "autoinhibitory" helix 12 conformation.
Similar articles
-
Structural basis for the deactivation of the estrogen-related receptor gamma by diethylstilbestrol or 4-hydroxytamoxifen and determinants of selectivity.J Biol Chem. 2004 Aug 6;279(32):33639-46. doi: 10.1074/jbc.M402195200. Epub 2004 May 24. J Biol Chem. 2004. PMID: 15161930
-
Structural characterization of a subtype-selective ligand reveals a novel mode of estrogen receptor antagonism.Nat Struct Biol. 2002 May;9(5):359-64. doi: 10.1038/nsb787. Nat Struct Biol. 2002. PMID: 11953755
-
Coactivator peptides have a differential stabilizing effect on the binding of estrogens and antiestrogens with the estrogen receptor.Mol Endocrinol. 1999 Nov;13(11):1912-23. doi: 10.1210/mend.13.11.0373. Mol Endocrinol. 1999. PMID: 10551784
-
Implications of the binding of tamoxifen to the coactivator recognition site of the estrogen receptor.Endocr Relat Cancer. 2008 Dec;15(4):851-70. doi: 10.1677/ERC-07-0281. Epub 2008 Aug 28. Endocr Relat Cancer. 2008. PMID: 18755852 Review.
-
A structural biologist's view of the oestrogen receptor.J Steroid Biochem Mol Biol. 2000 Nov 30;74(5):261-8. doi: 10.1016/s0960-0760(00)00102-3. J Steroid Biochem Mol Biol. 2000. PMID: 11162934 Review.
Cited by
-
Design of a platinum-acridine-endoxifen conjugate targeted at hormone-dependent breast cancer.Chem Commun (Camb). 2013 Mar 25;49(24):2415-7. doi: 10.1039/c3cc38957j. Chem Commun (Camb). 2013. PMID: 23416453 Free PMC article.
-
TMEM97/Sigma 2 Receptor Increases Estrogen Receptor α Activity in Promoting Breast Cancer Cell Growth.Cancers (Basel). 2023 Dec 2;15(23):5691. doi: 10.3390/cancers15235691. Cancers (Basel). 2023. PMID: 38067394 Free PMC article.
-
Steroid receptor-coregulator transcriptional complexes: new insights from CryoEM.Essays Biochem. 2021 Dec 17;65(6):857-866. doi: 10.1042/EBC20210019. Essays Biochem. 2021. PMID: 34061186 Free PMC article.
-
In silico design of novel bioactive molecules to treat breast cancer with chlorogenic acid derivatives: a computational and SAR approach.Front Pharmacol. 2023 Dec 12;14:1266833. doi: 10.3389/fphar.2023.1266833. eCollection 2023. Front Pharmacol. 2023. PMID: 38152692 Free PMC article.
-
Identification of antidiabetic inhibitors from Allophylus villosus and Mycetia sinensis by targeting α-glucosidase and PPAR-γ: In-vitro, in-vivo, and computational evidence.Saudi Pharm J. 2024 Jan;32(1):101884. doi: 10.1016/j.jsps.2023.101884. Epub 2023 Nov 25. Saudi Pharm J. 2024. PMID: 38090733 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
- Actions
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
